<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04389216</url>
  </required_header>
  <id_info>
    <org_study_id>ICPS002/20</org_study_id>
    <nct_id>NCT04389216</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation (RFA) in Breast Tumors</brief_title>
  <acronym>RFA</acronym>
  <official_title>Radiofrequency Ablation in Breast Tumors in Early Stages</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To validate the efficacy and safety of the cool-tip ablation method for breast tumors smaller
      than 2 cm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, phase II-III study, which will include a series of cases of 30 patients. The
      hospitals involved will be Bellvitge University Hospital and Hospital del Mar.

      Efficacy was evaluated according magnetic resonance image and biopsy of the breast 1 month
      after the procedure.

      Patients will be followed up over a 2-year period to assess cosmetic results, short and
      long-term complications and possible recurrences.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Radiofrequency ablation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI post-RFA</measure>
    <time_frame>1 month after procedure</time_frame>
    <description>Magnetic Resonance Image after Radiofrequency ablation to confirmate complete disappearance of tumor contrast enhancement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BAG post-RFA</measure>
    <time_frame>1 month after procedure</time_frame>
    <description>Breast biopsy after Radiofrequency to confirmate absence of viable tumor tissue using NADH, CK18 and CK19 stainings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Adverse effects related to radiofrequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality</measure>
    <time_frame>1 month after procedure</time_frame>
    <description>Breast-Q</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>Radiofrequency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiofrequency Ablation of breast cancer tumour by Cool-tip electrode.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cool-tip electrode for Radiofrequency Ablation</intervention_name>
    <description>Radiofrequency ablation of the tumour in the surgery group, associated whith axillary surgery when applicable</description>
    <arm_group_label>Radiofrequency</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infiltrating ductal carcinoma according the biopsy of the breast,

          -  Tumor visible by ultrasound, smaller than 2 cm,

          -  Located &gt; 1 cm from the chest wall and the skin.

        Exclusion Criteria:

          -  Personal antecedents of breast cancer

          -  Multifocality or intraductal carcinoma

          -  Lobular infiltrating carcinoma

          -  Neoadjuvant therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amparo Garcia-Tejedor, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amparo Garcia-Tejedor, MDPhD</last_name>
    <phone>660223417</phone>
    <email>agarciat@bellvitgehospital.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amparo Garcia-Tejedor, MDPhD</last_name>
      <phone>0034-660223417</phone>
      <email>agarciat@bellvitgehospital.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Argudo, MD</last_name>
      <email>nargudo@parcdesalutmar.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 3, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Amparo Garcia-Tejedor</investigator_full_name>
    <investigator_title>PRINCIPAL INVESTIGATOR</investigator_title>
  </responsible_party>
  <keyword>radiofrequency</keyword>
  <keyword>early stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

